FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Westphal Christoph H</u>					2. Issuer Name and Ticker or Trading Symbol Flex Pharma, Inc. [FLKS]										p of Reportin blicable) ctor	g Perso	,		
	X PHARM	(First) (Middle) ARMA, INC. DN STREET				3. Date of Earliest Transaction (Month/Day/Year) 05/27/2016									Offic belov	er (give title v) President	t and (Other (specify below)	
(Street) BOSTON (City)			02199 Zip)		- 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a		and 5) Secur Benef Owne		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) (D)	or Pri	ce	Reported Transaction(s) (Instr. 3 and 4)		("		(Instr. 4)
Common Stock			05/27/2016				P		17,300	A	\$1	2.68(1)	3,1	3,153,861		I	See notes ⁽²⁾⁽³⁾		
Common Stock			05/31/2016				P		5,000	A	. \$1	2.66 ⁽⁴⁾ 3,		,158,861		Ι	See notes ⁽³⁾⁽⁵⁾		
Common Stock													3,925,248		D				
		Та	ble II -								osed of, convertib				wned				
1. Title of Derivative Security (Instr. 3)	perivative Conversion Date Execution Date, security or Exercise (Month/Day/Year) if any			on Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expirati (Month/	on Da		7. Title and Amount of Securities Underlying Derivative Security (Instrand 4)		Deri Sec (Ins	B. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ov Fo Dii or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Numb of Shares						

Explanation of Responses:

- 1. The price in Column 4 is a weighted average purchase price. The prices actually received ranged from \$12.54 to \$12.80. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
- 2. On May 27, 2016, Longwood Fund III, L.P. ("Longwood Fund III") purchased 17,300 shares of common stock of the Issuer (the "Common Shares"). Following such purchase, Longwood Fund III owned 456,597 Common Shares and Longwood Fund II, L.P. ("Longwood Fund II") owned 2,697,264 Common Shares.
- 3. Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund III and Longwood Fund III GP, LLC is the ultimate General Partner of Longwood Fund III. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC and Longwood Fund III GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the Issuer's securities held by Longwood Fund II and Longwood Fund III (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.
- 4. The price in Column 4 is a weighted average purchase price. The prices actually received ranged from \$12.41 to \$13.00. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
- 5. On May 31, 2016, Longwood Fund III purchased 5,000 Common Shares. Following such purchase, Longwood Fund III owned 461,597 Common Shares and Longwood Fund II owned 2,697,264 Common

Remarks:

/s/ Robert Hadfield, Attorney-

06/01/2016

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

** Signature of Reporting Person

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.